Effect of alendronate on cultured normal human osteoblasts

Bone

Volumn 22, Issue 3, 1998, Pages 233-239

  Garcia Moreno C ^a   Serrano, Sergio ^b   Nacher, M ^a   Farre M ^a   Diez A ^b   Marinoso M L ^b   Carbonell, J ^b   Mellibovsky, L ^b   Nogues X ^b   Ballester, J ^b   Aubia J ^b  

^a Instituto de Investigaciones   (Spain)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

Alendronate; Bone; In vitro; Normal human osteoblast

Indexed keywords

ALENDRONIC ACID; COLLAGEN; DNA;

ARTICLE; BONE MINERAL; BONE MINERALIZATION; CELL COUNT; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; OSTEOBLAST;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; CALCIUM; CELL COUNT; CELL SURVIVAL; CELLS, CULTURED; COLLAGEN; DNA; FEMALE; HUMANS; MALE; OSTEOBLASTS; THYMIDINE;

EID: 0032031289     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(97)00270-6     Document Type: Article

References (36)

1. 1. Anderson, C. Preparation of calcified tissues for light microscopic histochemistry. In: Dickson, G. R., Ed. Methods of Calcified Tissue Preparation. Amsterdam: Elsevier; 1984.
2. 2. Arlot, M. C., Meunier, P. J., Chavassieux, P., Recker, R. R., Reda, C., Wei, L., and Yates, A. J. Effects of long-term alendronate treatment for postmenopausal osteoporosis on bone histomorphometry [abstract]. J Bone Miner Res 10:P248; 1995.
3. 3. Balena, R., Toolan, B. C., Shea, M., Markatos, A., Myers, E. R., Lee, S. C., Opas, E. E., Seedor, J. G., Klein, H., Frankenfield, D., Quartuccio, H., Fioravanti, C., Clair, J., Brown, E., Hayes, W. C., and Rodan, G. A. The effects of two year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry and bone strength in ovariectomized non-human primates. J Clin Invest 92:2577-2586; 1993.
4. 4. Boyce, B. F., Fogelman, I., Ralston, S., Smith, L., Johnston, E., and Boyle, I. T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet i:821-824; 1984.
5. 5. Carano, A., Teitelbaum, S. L., Konsek, J. D., Schlesinger, P. H., and Blair, H. C. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 85:456-461; 1990.
6. 6. Chesnut, C. H., III. McClung, M. R., Ensrud, K. E., Bell, N. H., Genant, H. K., Harris, S. T., Singer, F. R., Stock, J. L., Yood, R. A., Delmas, P. D., Kher, U., Pryor-Tillotson, S., and Santora, A. C., II. Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling. Am J Med 99:144-152; 1995.
7. 7. Fleisch, H. Bisphosphonates: History and experimental basis. Bone 8:528-538; 1987.
8. 8. Gertz, B. J., Holland, S. D., Kline, W. F., Matuszewski, B. K., and Porras, A. G. Clinical pharmacology of alendronate sodium. Osteopor Int (Suppl.3):S13-S16; 1993.
9. 9. Howard, T., Kimmel, D., Recker, R., Bone, H., Bankhurst, A., Barret, J., Wei, L., and Yates, A. J. Mineralization and turnover of bone in elderly women with osteoporosis treated with oral alendronate [abstract]. J Bone Miner Res 10: P272; 1995.
10. 10. Ishii, T., Saito, T., Morimoto, K., Takeuchi, Y., Asano, S., Kumegawa, M., Ogata, E., and Matsumoto, T. Estrogen stimulates the elaboration of cell/matrix surface-associated inhibitory factor of osteoclastic bone resorption from osteoblastic cells. Biochem Biophys Res Commun 191:495-502; 1993.
11. 11. Jowsey, J., Riggs, B. L., Kelly, P. J., Hoffman, D. L., and Bordier, P. The treatment of osteoporosis with disodium ethane-[-hydroxy-], l-diphosphonate. J Lab Clin Med 78:574-584; 1971.
12. 12. Kanis, J. A., Gertz, B. J., Singer, F., and Ortolani, S. Rationale for the use of alendronate in osteoporosis. Osteopor Int 5:1-13; 1995.
13. 13. Kassem, M., Mosekilde, L., and Eriksen, E. F. Effects of fluoride on human bone cells in vitro: Differences in responsiveness between stromal osteoblast precursors and mature osteoblasts. Eur J Endocrinol 130:381-386; 1994.
14. 14. Lian, J. B., Coutts, M., and Canalis, E. Studies of hormonal regulation of osteocalcin synthesis in cultured fetal rat calvaria. J Biol Chem 260:8706-8710; 1985.
15. 15. Liberman, U. A., Weiss, S. R., Bröll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriquez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., Seeman, E., Recker, R. R., Capizzi, T., Santora, A. C., II, Lombardi, A., Shah, R. V., Hirsch, L. J., and Karpf, D. B. Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443; 1995.
16. 16. Marie, P. J., Lomri, A., Sabbagh, A., and Basle, M. Culture and behavior of osteoblastic cells isolated from normal trabecular bone surfaces. In Vitro Cell Devel Biol 25:373-380; 1989.
17. 2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 3:23-30; 1990.
18. 18. Nacher, M., Aubia, J., Serrano, S., Mariñoso, M. L., Hernández, J., Bosch, J., Díez, A., Puig, J. M., and Lloveras, J. Effect of cyclosporine A on normal human osteoblasts in vitro. Bone Miner 26:231-243; 1994.
19. 19. Nussbaum, S. R., Warrell, R. P., Rude, R., Glusman, J., Bilezikian, J. P., Stewart, A. F., Stepanavage, M., Sacco, J. F., Averbuch, S. D., and Gertz, B. J. Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol 11:1618-1623; 1993.
20. 20. O'Doherty, D. P., Bickerstaff, D. R., McCloskey, E. V., Hamdy, N. A. T., Beneton, M. N. C., Harris, S., Mian, M., and Kanis, J. A. Treatment of Paget's disease of bone with amino-hydroxybutylidene bisphosphonate. J Bone Miner Res 5:483-491; 1990.
21. 21. O'Doherty, D. P., Gertz, B. J., Tindale, W., Seiberras, D. G., Survill, T. T., and Kanis, J. A. Effects of five daily 1h infusions of alendronate in Paget's disease of bone. J Bone Miner Res 7:81-87; 1992.
22. 22. Peterkofsky, B. and Diegelmann, R. Use of a mixture of proteinase-free collagenases for the specific assay of radiactive collagen in the presence of other proteins. Biochemistry 10:988-996; 1971.
23. 23. Ralston, S. J., Gardner, M. D., Dryborough, F. J., Jenkins, A. S., Cowan, R. A., and Boyle, I. T. Comparison of aminohydroxy-propylidene diphosphonate, mitramycin and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia. Lancet ii:1180-1182; 1985.
24. 24. Ralston, S. J., Patel, U., Fraser, W. D., Gallacher, S. J., Dryborough, F. J., Cowan, R. A., and Boyle, I. T. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet ii:1180-1182; 1989.
25. 25. Rodan, G. A. Bone mass homeostasis and bisphosphonate action. Bone 1:1-4; 1997.
26. 26. Rossini, M., Gatti, D., Zamberlan, N., Braga, V., Dorizzi, R., and Adami, S. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis. J Bone Miner Res 9:1833-1837; 1994.
27. 27. Sato, M. and Grasser, W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 5:31-40; 1990.
28. 28. Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., and Rodan, G. A. Bisphosphonate action: Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105; 1991.
29. 29. Schenk, R., Eggli, P., Felix, H., and Rosini, S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 38:342-349; 1986.
30. 30. Shani, M., Guenther, H. L., Fleisch, H., Collin, P. and Martin, T. J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004-2011; 1993.
31. 31. Tenenbaum, H. C., Torontali, M., and Sukhu, B. Effects of bisphosphonates and inorganic pyrophosphate on osteogenesis in vitro. Bone 13:249-255; 1992.
32. 32. Thompson, D. D., Seedor, J. G., Quartuccio, H., Solomon, H., Fioravanti, C., Davidson, J., Klein, H., Jackson, R., Clair, J., Frankenfield, D., Brown, E., Simmons, H. A., and Rodan, G. A. The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. J Bone Miner Res 7:951-960; 1992.
33. 33. Thompson, M. and Walsh, N. Hand Book of Inductibility-Coupled Plasma Spectrometry, 2nd ed. London: Blackie; 1980.
34. 34. Tsuchimoto, M., Azuma, Y., Higuchi, O., Sugimoto, I., Hirata, N., Kiyoki, M., and Yamamoto, I. Alendronate modulates osteogenesis of human osteoblastic cells in vitro. Jpn J Pharmacol 66:25-33; 1994.
35. 35. van Holten-Verzantvoort, A., Bijvoet, O. L. M., Cleton, F. J., Termans, J., Kroon, H. M., Harinck, H. I. J., Vermey, P., Elte, J. W. F., Neijt, J. P., Beex, L. V. A. M., and Blijham, G. G. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 2:983-985; 1987.
36. 36. Vitte, C., Fleisch, H., and Guenther, H. L. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 137: 2324-2333; 1996.